Epidiolex

Bank of America Merrill Lynch doubled down on its bullish thesis for GW Pharmaceuticals plc (NASDAQ: GWPH) and its flagship Epidiolex drug after attending the American Epilepsy Society's annual meeting. The Analyst Analysts Tazeen Ahmad maintained a Buy on GW Pharma with a $190 price...

GW Pharmaceuticals plc (NASDAQ: GWPH) Epidiolex drug and earlier-stage programs Sativex and CBDV will represent major catalysts for the stock in the near-term, in Cantor Fitzgerald's view.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW Pharmaceuticals with a $211 price...

GW Pharmaceuticals plc (NASDAQ: GWPH) reported financial results for its fiscal fourth quarter 2018. Compared to analysts' consensus estimates, the company reported a better-than-expected net loss, but its top line missed the expectations. What Happened For the quarter ended Sept. 30, GW...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced incremental positive news on its lead cannabinoid product candidate Epidiolex, sending the stock higher. What Happened GW Pharma announcedpositive results for a second, late-stage study that evaluated its Epidiolex oral solution for treatment...

Leerink is taking a bullish stance on GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH), with a thesis centering around the company's lead drug Epidiolex; the drug Sativex; GW's involvement in the epilepsy market and its cannabinoid science platform. The Analyst Leerink's Marc Goodman...

The global cannabis industry took two big steps forward this week. On Oct. 31, Mexico’s Supreme Court said the laws that ban recreational weed are unconstitutional, essentially opening the door for a potential legalization of pot in the future. The second major development took place across...

Two big news items dominated the cannabis industry this week: the re-scheduling of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s cannabis-derived drug, Epidiolex, from the Schedule I category to the Schedule V category; and High Times’ acquisition of Dope Magazine for $11.2 million in...

Amid the controversies surrounding the legalization of cannabis and associated products, gradual advancements have been made this year. As of Sept. 27, a specific type of cannabidiol, or CBD oil will be federally legal in the United States. What Happened The U.S. Drug Enforcement Administration...

Even before word of the DEA's landmark rescheduling of cannabidiol (CBD) for GW Pharmaceuticals (NASDAQ: GWPH) FDA-approved Epidiolex, the cannabis market has had a hot summer. Medical cannabis is now legal in 31 states and the District of Columbia, with adult-use markets open in 9 of them plus...

By Sunday night, the U.S. Drug Enforcement Administration is expected to reclassify GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s Epidiolex to allow medicinal use. This could open the therapy to a new and promising market. The Analyst  Morgan Stanley analyst David Lebowitz ...